Amarin to Present at the Rodman & Renshaw 2015 Global Investment Conference

BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 09/02/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Rodman & Renshaw 2015 Global Investment Conference in New York City on Wednesday, September 9, 2015, at 4:40 p.m. ET.

A live audio webcast of the presentation will be available at:

http://wsw.com/webcast/rrshq25/amrn

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

   Investor Relations:Michael Farrell  Investor Relations and Corporate Communications Amarin Corporation plc In U.S.: +1 (908) [email protected] Morrell Trout Group  In U.S.: +1 (646) [email protected] Inquiries:Lee Davies Makovsky In U.S.: +1 (212) [email protected]

Source: Amarin Corp. Plc

You May Also Be Interested In

• Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
• Kimball Electronics, Inc. Announces Date For Reporting Third Quarter Fiscal Year 2024 Financial Results
• Nokia Corporation: Repurchase of own shares on 24.04.2024